DOI QR코드

DOI QR Code

Preparation, Characterization and Cytotoxicity of Silibinin-Containing Nanoniosomes in T47D Human Breast Carcinoma Cells

  • Amiri, Boshra (Chemistry faculty, Islamic Azad University of Shahrood) ;
  • Ebrahimi-Far, Meysam (Department of Toxicology, Faculty of Pharmacy, Islamic Azad University) ;
  • Saffari, Zahra (Pilot Nanobiotechnology Dep., Pasteur Institute of Iran) ;
  • Akbarzadeh, Azim (Pilot Nanobiotechnology Dep., Pasteur Institute of Iran) ;
  • Soleimani, Esmaeil (Chemistry faculty, Islamic Azad University of Shahrood) ;
  • Chiani, Mohsen (Pilot Nanobiotechnology Dep., Pasteur Institute of Iran)
  • Published : 2016.08.01

Abstract

Background: Breast cancer is one of the most frequent cancer types within female populations. Silibinin is a chemotherapeutic agent ative against cancer. Niosomes are biodegradable, biocompatible, safe and effective carriers for drug delivery. Objective:To prepare nanoniosomal silibinin and evaluate its cytotoxicity inthe T-47D breast cancer cell line. Materials and Methods: Niosomes were prepared by reverse phase evaporation of a mixture of span 20, silibinin, PEG-2000 and cholesterol in chloroform and methanol solvent (1:2 v/v). The solvent phase was evaporated using a rotary evaporator and the remaining gel phase was hydrated in phosphate buffer saline. Mean size, size distribution and zeta potential of niosomes were measured with a Zetasizer instrument and then nanoparticles underwent scanning electron microscopy. The drug releasing pattern was evaluated by dialysis and the cytotoxicity of nanoniosomes in T-47D cells was assessed by MTT assay. Results: Particle size, size variation and zeta potential of the niosomal nanoparticles were measured as $178.4{\pm}5.4nm$, $0.38{\pm}0.09$ and $-15.3{\pm}1.3mV$, respectively. The amount of encapsulated drug and the level of drug loading were determined $98.6{\pm}2.7%$ and $22.3{\pm}1.8%$, respectively; released drug was estimated about $18.6{\pm}2.5%$ after 37 hours. The cytotoxic effects of nanoniosome were significantly increased when compared with the free drug. Conclusions: This study finding suggests that silibinin nanoniosomes could serve as a new drug formulation for breast cancer therapy.

Keywords

Silibinin;nanoniosomes;breast cancer;T-47D cells

Acknowledgement

Supported by : Pilot Nanobiotechnology Department, Pasteur Institute of Iran

References

  1. Armstrong K, Eisen A, Weber B (2000). Assessing the risk of breast cancer. New Engl J Med, 342, 564-71. https://doi.org/10.1056/NEJM200002243420807
  2. Astete CE, Sabliov CM (2006). Synthesis and characterization of PLGA nanoparticles. J Biomater Sci Polym Ed, 17, 247-89. https://doi.org/10.1163/156856206775997322
  3. Bhatia N, Zhao J, Wolf DM, et al (1999). Inhibition of human carcinoma cell growth and DNA synthesis by silibinin, an active constituent of milk thistle, comparison with silymarin. Cancer Letters, 1, 77-84.
  4. Cao X, Deng W, Fu M, et al (2013). Seventy-two-hour release formulation of the poorly soluble drug silybin based on porous silica nanoparticles, in vitro release kinetics and in vitro/in vivo correlations in beagle dogs. Eur J Pharm Sci, 48, 64-71 https://doi.org/10.1016/j.ejps.2012.10.012
  5. CHO HJ, Suh DS, Moon SH, et al (2013). Silibinin inhibits tumor growth through downregulation of extracellular signal-regulated kinase and Akt in vitro and in vivo in human ovarian cancer cells. J Agricultural Food Chem, 17, 4089-96.
  6. Coley HM (2008). Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treatment Reviews, 34, 378-90. https://doi.org/10.1016/j.ctrv.2008.01.007
  7. El-Samaligy MS1, Afifi NN, Mahmoud EA (2006). Increasing bioavailability of silymarin using a buccal liposomal delivery system, preparation and experimental design investigation. Int J Pharmaceutics, 1, 140-48.
  8. El-Sherbiny IM, Abdel-Mogib M, M Dawindar AZ, et al (2011). Biodegradable pH-responsive alginate-poly (lactic-coglycolic acid) nano/micro hydrogel matrices for oral delivery of silymarin. Carbohydrate Polymers, 3, 1345-54.
  9. Fang JY, Hong CT, Chiu WT, et al (2001). Effect of liposomes and niosomes on skin permeation of enoxacin. Int J Pharmaceutics, 1, 61-72.
  10. Larsen ME, Rowntree J, Young AM, et al (2008). Chemotherapy side-effect management using mobile phones. Conf Proc IEEE Eng Med Biol Soc, 2008, 5152-5.
  11. Mansour HM, Rhee YS, Wu X (2009). Nanomedicine in pulmonary delivery. Int J Nanomedicine, 4, 299-319.
  12. Lin CM, Chen YH, Ma HP, et al (2012). Silibinin inhibits the invasion of IL-6-stimulated colon cancer cells via selective JNK/AP-1/MMP-2 modulation in vitro. J Agricultural Food Chem, 51, 12451-57.
  13. Rostas JW, Dyess DL (2011). Current operative management of breast cancer, an age of smaller resections and bigger cures. International J Breast Cancer, 2012, 1-7.
  14. Sharma G, Singh RP, Chan DC, et al (2002). Silibinin induces growth inhibition and apoptotic cell death in human lung carcinoma cells. Anticancer Res, 3, 2649-55.
  15. Singletary SE (2003). Rating the risk factors for breast cancer. Ann Surg, 237, 474-82.
  16. Sun N, Wei X, Wu B, et al (2008). Enhanced dissolution of silymarin/polyvinylpyrrolidone solid dispersion pellets prepared by a one-step fluid-bed coating technique. Powder Technol, 1, 72-80.
  17. Verschoyle RD, Greaves P, Patel K, et al (2008). Evaluation of the cancer chemopreventive efficacy of silibinin in genetic mouse models of prostate and intestinal carcinogenesis, relationship with silibinin levels. Eur J Cancer, 6, 898-906.
  18. Wang Y, Zhang D, Liu Z, et al (2010). In vitro and in vivo evaluation of silybin nanosuspensions for oral and intravenous delivery. Nanotechnol, 21, 155104. https://doi.org/10.1088/0957-4484/21/15/155104
  19. Wang J, Chen B, Chen J, et al (2011). Synthesis and antitumor efficacy of daunorubicin-loaded magnetic nanoparticles. Int J Nanomedicine, 6, 203-11.
  20. Wei Y, Ye X, Shang X, et al (2012). Enhanced oral bioavailability of silybin by a supersaturatable self-emulsifying drug delivery system (S-SEDDS). Colloids and Surfaces A, Physicochemical and Engineering Aspects, 396, 22-28.
  21. Williams J, Lansdown R, Sweitzer R, et al (2003). Nanoparticle drug delivery system for intravenous delivery of topoisomerase inhibitors. J Controlled Release, 1, 167-72.
  22. Yu JN1, Zhu Y, Wang L, et al (2010). Enhancement of oral bioavailability of the poorly water-soluble drug silybin by sodium cholate/phospholipid-mixed micelles. Acta Pharmacologica Sinica, 6, 759-64.
  23. Zarei M, Norouzian D, Chiani M, et al (2013). Advantages of paclitaxel-loaded nan niosomes to nanliposomal formulation, an in vitro study. Int J Life Sc Bt Pharm Res, 2, 335-342
  24. Zhang JQ, Liu J, Li XL, et al (2007). Preparation and characterization of solid lipid nanoparticles containing silibinin. Drug Delivery, 6, 381-87.
  25. Zhang Z, Feng SS (2006). The drug encapsulation efficiency, in vitro drug release, cellular uptake and cytotoxicity of paclitaxel-loaded poly (lactide)-tocopheryl polyethylene glycol succinate nanoparticles. Biomaterials, 21, 4025-33.